Composition with cell protection effect and application thereof

Abstract

The invention belongs to but not limited to the technical field of biomedicine, and discloses a composition with a cell protection effect and application thereof, the composition comprises five monomers of cycloastragenol, resveratrol, ginsenoside, tetrahydrocurcumin and cellulose, and can also comprise a moisturizing composition and a moisturizing composition. The composition provided by the invention can accurately act on vaginal smooth muscle cells and gland cells, and can be used for recovering or improving endocrine balance by improving cell activity, promoting elastin synthesis and repairing cell injury in multiple ways, improving telomerase activity of a reproductive system and regulating immune response, so that the curative effect of the composition is improved. Various injury factors such as exogenous factors, traction of production machinery and age increase are effectively resisted, and the method has wide application prospects in the fields of postpartum reproductive system rehabilitation, maintenance of normal functions of the reproductive system, prevention and improvement of conditions such as vagina relaxation, dryness and poor injury repair and the like, and prevention and treatment of related diseases of the reproductive system and health care.

Description

Technical Field

[0001] The present invention belongs to but is not limited to the field of biomedical technology, and in particular relates to a composition with cell protection effect and application thereof. Background Art

[0002] Currently, cycloastragenol is a white crystalline powder with a melting point of approximately 220–222°C. It is stable at room temperature but easily degrades under light or high temperature. It has low water solubility and is soluble in organic solvents such as methanol and ethanol. Cycloastragenol is a key component extracted from Astragalus membranaceus. It belongs to the triterpenoid saponin class and contains multiple hydroxyl groups and glycosidic bonds. It has significant antioxidant and anti-inflammatory properties. Studies have shown that cycloastragenol can promote cell self-repair and alleviate oxidative stress damage. It can activate telomerase to delay cell aging and exhibit immunomodulatory and anti-fatigue effects. Furthermore, cycloastragenol can enhance telomerase activity, thereby improving the proliferation of CD3 and CD8 T cells. It can also modulate intracellular signaling pathways, such as by activating the PI3K-AKT pathway, to promote cell survival, proliferation, and differentiation.

[0003] Resveratrol appears as white or pale yellow crystals with a melting point of 260–262°C. It is stable in acidic environments but readily hydrolyzes under alkaline conditions. It has poor water solubility but is soluble in solvents such as ethanol and propylene glycol. Resveratrol is a polyphenol compound found in grape skins and red wine. Its structure consists of a double benzene ring and a triene chain and is known for its potent antioxidant and anti-inflammatory properties. It can help slow the process of apoptosis by regulating cell metabolism and protecting telomeres, and it also has beneficial effects on cardiovascular health and the immune system. For example, resveratrol regulates cell metabolism and survival by activating the SIRT1 protein, exerting anti-aging, anti-cancer, and anti-inflammatory effects.

[0004] Ginsenosides are colorless or white crystalline powders with high solubility in water but low solubility in organic solvents. Their melting point varies depending on the specific type, ranging from 200–300°C. They are stable under neutral or weakly acidic conditions but easily hydrolyze in strong acidic / alkaline environments. Ginsenosides are the main active ingredients in ginseng. They are triterpenoid saponins containing multiple hydroxyl groups and glycosidic bonds, and have immune-enhancing, anti-fatigue, and antioxidant properties. Ginsenosides have cellular protective effects and promote physiological recovery, regulating cellular energy metabolism and signal transduction. Studies have shown that ginsenosides can increase telomerase activity, prolonging or maintaining normal cellular function. Ginsenosides promote cell proliferation and survival by regulating cell signaling pathways (such as PI3K / AKT), and have anti-fatigue, anti-stress, and cognitive-enhancing biological activities.

[0005] Tetrahydrocurcumin is a yellow to orange crystalline solid with a melting point of 175–177°C. It is stable at room temperature, but may degrade under light or elevated temperatures. It has low water solubility and is readily soluble in solvents such as ethanol and chloroform. As a reduction product of curcumin, its symmetrical diarylheptane structure imparts antioxidant, anti-inflammatory, and antimutagenic properties. Tetrahydrocurcumin is an active derivative of curcumin with a symmetrical diarylheptane structure, resulting in enhanced bioavailability and antioxidant, anti-inflammatory, and anti-tumor properties. Furthermore, tetrahydrocurcumin reduces oxidative damage by regulating signaling pathways such as NF-κB and Nrf2, exhibiting anti-aging, anti-inflammatory, and potential anticancer activities. However, limited research has examined the effects of tetrahydrocurcumin on telomerase, and its direct effect on telomerase remains unclear.

[0006] Cellulose is a white or pale yellow amorphous powder that is insoluble in water but soluble in copper ammonia solutions or alkaline solutions. It is stable at room temperature and easily hydrolyzed in strong acid / alkaline environments. Cellulose, a natural polysaccharide, is a polymer of glucose linked by β-1,4 glycosidic bonds. It has water absorption and swelling properties and is primarily used to support cell structure and provide nutritional support. Studies have shown that cellulose can regulate the balance of intestinal flora, lower serum cholesterol, and improve blood sugar metabolism, making it a core component of dietary fiber. It helps maintain digestive health in the body and may also indirectly affect reproductive system physiological processes by improving metabolic status.

[0007] Through investigation and research, it was found that the problems and defects of the existing technology are: the existing technology has not yet found that cycloastragenol, resveratrol, ginsenosides, tetrahydrocurcumin and cellulose monomers and the combination of the five can promote the survival and functional recovery of uterine and vaginal smooth muscle cells after damage, improve the contractile function of the reproductive system, restore the secretory function of reproductive tract cells, and enhance the telomerase activity and immunity of the reproductive system. The problem of promoting the repair of vaginal smooth muscle and elastic fibers after childbirth and causing vaginal smooth muscle damage and birth canal relaxation in patients after childbirth has not been solved; the problem of the normal structure and function of reproductive tract cells being destroyed due to various endogenous and exogenous damage factors has not been solved, such as a significant decrease in cell viability, secretory dysfunction, and decreased immune function, which further aggravates cell damage and death, leading to uncomfortable symptoms such as genital dryness and itching, and also increases the chance of pathogen infection; the problem of the genital tract mucosa becoming thinner and atrophied with age, the metabolism of smooth muscle cells and glandular cells slows down, the cell renewal rate decreases, and the elastin synthesis decreases, causing the elasticity and lubrication of the reproductive tract to be gradually lost, and symptoms such as dryness and pain are prone to occur. Moreover, when exposed to external stimuli, it is more prone to damage and the repair ability is weakened. These problems are still clinical problems, and there is still a lack of satisfactory means in clinical practice, which seriously affects the quality of life. Summary of the Invention

[0008] In response to the problems existing in the prior art, the present invention provides a composition with cell protection effect, a preparation method and application.

[0009] The present invention is achieved in this way: a composition with cell protection effect comprises, by weight, 0.1% to 5% of cycloastragenol, 0.5% to 10% of resveratrol, 0.1% to 5% of ginsenoside, 0.1% to 2% of tetrahydrocurcumin and 1% to 10% of cellulose.

[0010] Furthermore, the composition is composed of 0.1% to 5% of cycloastragenol, 0.5% to 10% of resveratrol, 0.1% to 5% of ginsenoside, 0.1% to 2% of tetrahydrocurcumin, 1% to 10% of cellulose, 1.7% to 2.2% of a moisturizing composition, and the remainder purified deionized water in parts by mass.

[0011] Furthermore, the moisturizing composition consists of hyaluronic acid and collagen.

[0012] Furthermore, the composition is composed of 0.1% to 5% of cycloastragenol, 0.5% to 10% of resveratrol, 0.1% to 5% of ginsenoside, 0.1% to 2% of tetrahydrocurcumin, 1% to 10% of cellulose, 12% to 22% of moisturizing composition and the balance of purified deionized water in parts by mass.

[0013] Furthermore, the mass fraction of the moisturizing composition is 12% to 22%, and the composition ingredients can be composed of any two or more of sucrose, sorbitol, glycerin, propylene glycol, chondroitin sulfate, hyaluronic acid, sulfated mucopolysaccharide, carolinic acid, and atelocollagen.

[0014] Furthermore, the structural formulas of cycloastragenol, resveratrol, ginsenoside, tetrahydrocurcumin and cellulose are as follows:

[0015]

[0016]

[0017] Another object of the present invention is to provide a method for preparing a composition having a cell-protective effect, comprising:

[0018] Cycloastragenol, resveratrol, ginsenoside, tetrahydrocurcumin and cellulose are mixed with distilled water and stirred uniformly to obtain a composition of the cycloastragenol, resveratrol, ginsenoside, tetrahydrocurcumin and cellulose.

[0019] Furthermore, the preparation method specifically comprises the following steps:

[0020] Step 1, weighing cycloastragenol, resveratrol, ginsenoside, tetrahydrocurcumin, cellulose, and a moisturizing composition or a moisturizing composition according to proportion;

[0021] Step 2: dissolving cycloastragenol, resveratrol, ginsenosides, tetrahydrocurcumin and cellulose in a water replenishing composition or a moisturizing composition solution, and stirring to obtain a homogeneous solution;

[0022] Step 3: Add purified ionized water to the homogeneous solution to a full amount and adjust the volume to obtain the cycloastragenol, resveratrol, ginsenoside, tetrahydrocurcumin and cellulose composition.

[0023] Another object of the present invention is to provide a composition for protecting vaginal smooth muscle cells and glandular cells and promoting elastin synthesis, for use in preparing products for repairing postpartum vaginal and uterine smooth muscle cells and promoting elastin synthesis, maintaining the elasticity and function of the reproductive tract, and enhancing or repairing the activity of glandular cells in the reproductive system.

[0024] Another object of the present invention is to provide a compound for promoting the activity of vaginal smooth muscle cells, promoting contraction ability and promoting elastin synthesis, comprising 0.1% to 2% of tetrahydrocurcumin, and the remaining ingredients being pure water or acceptable excipients.

[0025] In combination with the above technical solutions and the technical problems solved, the advantages and positive effects of the technical solutions to be protected by the present invention are as follows:

[0026] The cycloastragenol, resveratrol, ginsenoside, tetrahydrocurcumin and cellulose composition of the present invention can repair reproductive tract cell damage, enhance cell vitality, protect smooth muscle cells and glandular cells, and promote smooth muscle to synthesize elastin.

[0027] The cycloastragenol, resveratrol, ginsenoside, tetrahydrocurcumin and cellulose composition of the present invention can promote the morphology maintenance and function of vaginal smooth muscle cells and glandular cells of animals.

[0028] The present invention discovers that a composition of cycloastragenol, resveratrol, ginsenosides, tetrahydrocurcumin, and cellulose monomers can repair damaged reproductive tract cells in female animals, repair the postpartum reproductive system, enhance the vitality of vaginal smooth muscle cells and uterine glandular cells, and promote elastin synthesis in smooth muscle. These activities have not been reported domestically or internationally. This composition, through a unique preparation method, combines endocrine regulation, immune enhancement, vitality promotion, and elastin synthesis. Simultaneously, the composition has direct or indirect effects on telomere length and telomerase, thereby influencing the repair and regeneration of the reproductive system. The novel composition of the present invention exhibits distinct activities compared to previously reported activities and exhibits greater specificity and effectiveness than traditional treatments, demonstrating significant innovation.

[0029] The technical solution of the present invention fills the technical gap in the activity and application of cycloastragenol, resveratrol, ginsenoside, tetrahydrocurcumin, cellulose monomer and a combination of the five of them in repairing the postpartum reproductive system, promoting the vitality of vaginal smooth muscle cells and uterine gland cells and promoting the synthesis of elastin by smooth muscle.

[0030] The technical solution of the present invention is a new type of therapeutic product that is safe, effective, multi-target and has no obvious side effects. It also provides a new way to prevent and treat injuries to the birth canal and reproductive tract and maintain the health of the female reproductive system. BRIEF DESCRIPTION OF THE DRAWINGS

[0031] Figure 1 This is a flow chart of a method for preparing a composition with cell-protective effects provided by an embodiment of the present invention;

[0032] Figure 2 This is a comparison chart of the weight of postpartum mice and the drug administration group before and after the experiment provided in the present invention;

[0033] Figure 3 (a) is a normal mouse anatomy diagram provided in an embodiment of the present invention;

[0034] Figure 3 (b) is an anatomical diagram of a postpartum mouse provided in an embodiment of the present invention;

[0035] Figure 3 (c) is an anatomical diagram of a postpartum group of postpartum mice provided in an embodiment of the present invention;

[0036] Figure 3 (d) is an anatomical diagram of a postpartum mouse group administered with the composition provided in an embodiment of the present invention;

[0037] Figure 3 (e) is an anatomical diagram of a postpartum mouse cycloastragenol-administered group provided by an embodiment of the present invention;

[0038] Figure 3 (f) is an anatomical diagram of a postpartum mouse resveratrol-treated group provided by an embodiment of the present invention;

[0039] Figure 3 (g) is an anatomical diagram of a postpartum mouse ginsenoside-administered group according to an embodiment of the present invention;

[0040] Figure 3 (h) is an anatomical diagram of a tetrahydrocurcumin-treated postpartum mouse according to an embodiment of the present invention;

[0041] Figure 3 (i) is an anatomical diagram of a cellulose-administered group of postpartum mice provided in an embodiment of the present invention;

[0042] Figure 4 This is a comparison chart of the reproductive system quality of postpartum mice provided by an embodiment of the present invention;

[0043] Figure 5 This is a comparison chart of uterine contraction tension in postpartum mice provided by an embodiment of the present invention;

[0044] Figure 6 This is a graph showing the percentage of smooth muscle cell damage in postpartum mice provided by an embodiment of the present invention;

[0045] Figure 7 Schematic diagram of sm-troponin content in serum of postpartum mice provided by an embodiment of the present invention;

[0046] Figure 8 Schematic diagram of ET-1 content in serum of postpartum mice provided by an embodiment of the present invention;

[0047] Figure 9 is a statistical result graph of the immunoglobulin A (IgA) levels in the vaginal lavage fluid of each group of mice;

[0048] Figure 10 is the comparative data of relative telomerase activity levels in the vagina of mice in each group;

[0049] Figure 11 This is the comparative data of the relative telomerase activity levels in the uterus of each group of mice;

[0050] Figure 12 Figures are HE staining results of ovarian and vaginal sections of mice in each group; (a) normal group; (b) postpartum group; (c) combination administration group; (d) cycloastragenol administration group; (e) resveratrol administration group; (f) ginsenoside administration group; (g) tetrahydrocurcumin administration group; (h) cellulose administration group;

[0051] Figure 13 is the statistical result of the number of follicles in each group of mice;

[0052] Figure 14 is the statistical result graph of estradiol levels in the serum of mice in each group;

[0053] Figure 15 is the statistical result graph of testosterone levels in the serum of mice in each group;

[0054] Figure 16 This is a schematic diagram of detecting the viability of mouse vaginal smooth muscle cells cultured in vitro using the CCK-8 method provided in an embodiment of the present invention;

[0055] Figure 17 This is a graph showing the relative brightness ratio of intracellular elastin precursor in mouse vaginal smooth muscle cells provided by an embodiment of the present invention;

[0056] Figure 18 This is a schematic diagram of detecting the activity of mouse endometrial glandular cells cultured in vitro using the CCK-8 method provided in an embodiment of the present invention. DETAILED DESCRIPTION

[0057] In order to make the purpose, technical solutions and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with the embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not intended to limit the present invention.

[0058] An embodiment of the present invention provides a composition with cell protective effect, which includes, by weight, 0.1% to 5% of cycloastragenol, 0.5% to 10% of resveratrol, 0.1% to 5% of ginsenoside, 0.1% to 2% of tetrahydrocurcumin, and 1% to 10% of cellulose.

[0059] An embodiment of the present invention provides a method for preparing a composition having a cell-protective effect, comprising:

[0060] Aqueous solution preparation method: cycloastragenol, resveratrol, ginsenoside, tetrahydrocurcumin and cellulose are weighed in proportion to prepare an aqueous solution to obtain an aqueous solution of the composition.

[0061] An embodiment of the present invention provides a composition with a cell-protective effect, which is composed, by mass, of 0.1% to 5% cycloastragenol, 0.5% to 10% resveratrol, 0.1% to 5% ginsenoside, 0.1% to 2% tetrahydrocurcumin, 1% to 10% cellulose, 1.7% to 2.2% of a moisturizing composition, and the remainder purified deionized water.

[0062] The moisturizing composition consists of hyaluronic acid and collagen.

[0063] Hyaluronic acid, with an average molecular weight of 500,000 to 2,000,000, is a polysaccharide found in large quantities in many tissues within the body. Its physiological function is to allow water to enter intercellular spaces and bind with proteins to form a protein gel, which binds cells together, supporting normal cellular metabolism, retaining cellular moisture, protecting cells from pathogens, and enhancing immunity.

[0064] Collagen is the main component of the dermis and can improve the permeability of cell membranes. The absorption of collagen and hyaluronic acid on the skin surface can promote each other, allowing more nutrients of hyaluronic acid to be absorbed by the skin.

[0065] An embodiment of the present invention provides a composition with a cell-protective effect, which is composed, by mass, of 0.1% to 5% cycloastragenol, 0.5% to 10% resveratrol, 0.1% to 5% ginsenoside, 0.1% to 2% tetrahydrocurcumin, 1% to 10% cellulose, 12% to 22% of a moisturizing composition, and the remainder purified deionized water.

[0066] The mass fraction of the moisturizing composition is 12% to 22%, and the composition components can be composed of any two or more of sucrose, sorbitol, glycerol, propylene glycol, chondroitin sulfate, hyaluronic acid, sulfated mucopolysaccharide, carolinic acid, and atelocollagen.

[0067] The moisturizing composition component can provide a rich and moist feel, and can suppress the stickiness and astringency of the composition aqueous solution, giving users an excellent feeling of use.

[0068] like Figure 1 As shown, the embodiment of the present invention provides a method for preparing a composition with cell protective effect, and the sample preparation containing moisturizing ingredients and functions includes the following steps:

[0069] Step 1, weighing cycloastragenol, resveratrol, ginsenoside, tetrahydrocurcumin, cellulose, and a moisturizing composition or a moisturizing composition according to proportion;

[0070] Step 2: dissolving cycloastragenol, resveratrol, ginsenosides, tetrahydrocurcumin and cellulose in a water replenishing composition or a moisturizing composition solution, and stirring to obtain a homogeneous solution;

[0071] Step 3: Add purified ionized water to the homogeneous solution to a full amount and adjust the volume to obtain the cycloastragenol, resveratrol, ginsenoside, tetrahydrocurcumin and cellulose composition.

[0072] Example 1

[0073] An embodiment of the present invention provides a composition of cycloastragenol, resveratrol, ginsenosides, tetrahydrocurcumin and cellulose, which is composed, by weight, of 1% cycloastragenol, 2% resveratrol, 1% ginsenosides, 0.5% tetrahydrocurcumin and 8% cellulose, 1.7% hydrating composition, 19% moisturizing composition and the remainder purified deionized water, and the total weight is 100%.

[0074] The preparation method of the composition of cycloastragenol, resveratrol, ginsenoside, tetrahydrocurcumin and cellulose provided in an embodiment of the present invention comprises: dissolving cycloastragenol, resveratrol, ginsenoside, tetrahydrocurcumin and cellulose in sterile distilled water to obtain the composition.

[0075] The preparation method of the composition of cycloastragenol, resveratrol, ginsenoside, tetrahydrocurcumin and cellulose provided in an embodiment of the present invention further comprises:

[0076] Step 1, prepare the raw materials in parts by weight: 1% cycloastragenol, 2% resveratrol, 1% ginsenoside, 0.5% tetrahydrocurcumin, 8% cellulose, 1.7% hydrating composition, 19% moisturizing composition, and the balance is purified deionized water, and the deionized water is used to make up the difference;

[0077] Step 2: dissolving cycloastragenol, resveratrol, ginsenosides, tetrahydrocurcumin and cellulose in the water replenishing composition and the moisturizing composition solution, and stirring to obtain a homogeneous solution;

[0078] Step 3, adding purified ionized water to the full amount and adjusting the volume to obtain a composition of cycloastragenol, resveratrol, ginsenosides, tetrahydrocurcumin and cellulose;

[0079] Step 4: filling and capping: the mixture obtained after dissolution is filled into packaging bags using a filling machine and an automatic plastic film continuous sealing machine is used to seal the filled packaging bags;

[0080] Step 5: Inspect the intermediate product. If it is qualified, check for leaks and spray code. Use the inkjet printer to spray code the products one by one.

[0081] Step six: Packing and warehousing. The finished products are packaged and inspected, and qualified products are stored in the finished product warehouse.

[0082] The moisturizing composition provided in the embodiment of the present invention may be composed of hyaluronic acid and collagen.

[0083] The moisturizing composition provided by the embodiment of the present invention can suppress the stickiness and astringency of the aqueous solution of the composition, and has a rich and moist feeling, and an excellent feeling of use.

[0084] The moisturizing agent can be sucrose, sorbitol, glycerin, propylene glycol, chondroitin sulfate, hyaluronic acid, sulfated mucopolysaccharide, carolinic acid, atelocollagen, etc.

[0085] The embodiments of the present invention provide a composition of cycloastragenol, resveratrol, ginsenoside, tetrahydrocurcumin and cellulose, a preparation method and an application. Cycloastragenol, resveratrol, ginsenoside, tetrahydrocurcumin and cellulose monomers exhibit biological effects significantly different from their monomeric activity in specific combinations. Through high-throughput screening technology and virtual screening technology, the present invention found that the combination of these ingredients can not only repair reproductive system cell damage, but also significantly promote the vitality of reproductive tract smooth muscle cells and the synthesis of elastin. The mechanism of this composition is to maintain the function and contractile activity of cells by enhancing the activity of smooth muscle cells in a specific physiological environment. The application of this composition significantly improves the function of reproductive tract cells and has a high degree of specificity and efficacy. This discovery expands the understanding of the health and medical applications of these natural compounds.

[0086] An embodiment of the present invention provides a cycloastragenol, resveratrol, ginsenoside, tetrahydrocurcumin and cellulose composition. The cycloastragenol, resveratrol, ginsenoside, tetrahydrocurcumin and cellulose composition can be prepared into an aqueous solution, or the composition can be prepared into an acceptable excipient, solvent, dosage form or product.

[0087] 1. Specific application fields or related products of the present invention.

[0088] The composition of cycloastragenol, resveratrol, ginsenosides, tetrahydrocurcumin and cellulose provided in an embodiment of the present invention is used to prevent reproductive system aging in female animals. The specific application method includes: directly administering the prepared composition of cycloastragenol, resveratrol, ginsenosides, tetrahydrocurcumin and cellulose to the reproductive system of the female animal.

[0089] The present invention provides a composition with a cell-protective effect for use in preparing products related to repairing reproductive tract cell damage and promoting vaginal smooth muscle cell production, and the composition exerts its effect by promoting smooth muscle to synthesize elastin.

[0090] The present invention provides a composition with a cell-protective effect for use in preparing products related to promoting the activity of uterine and reproductive tract gland cells through a direct cell-protective effect.

[0091] The present invention provides a composition with a cell-protective effect for use in the preparation of products for promoting the recovery of glandular secretion function. The composition acts by activating the telomerase activity of the reproductive tract glands, thereby promoting the lubricating fluid production function.

[0092] The use of a composition provided in an embodiment of the present invention in the preparation of a product having a protective effect on cells damaged by the postpartum reproductive tract exerts its efficacy by increasing the telomerase activity of reproductive tract cells.

[0093] The application of a composition with cell protection provided in an embodiment of the present invention in the preparation of products related to accelerating postpartum reproductive tract recovery exerts its efficacy by enhancing immunity, improving the reproductive tract microenvironment, and enhancing anti-inflammatory effects.

[0094] The present invention provides a composition with a cell-protective effect for use in preparing products that promote the recovery of vaginal elastin and mucosa, improve vaginal lubricity, and improve the metabolism of smooth muscle cells and glandular cells, thereby restoring or improving the endocrine balance of the reproductive system.

[0095] The present invention provides an embodiment of a composition of cycloastragenol, resveratrol, ginsenosides, tetrahydrocurcumin, and cellulose for use in preparing an active ingredient for repairing reproductive tract cell damage, including increasing telomerase activity, promoting smooth muscle cell viability and elastin synthesis, enhancing immunity, regulating endocrine balance, and maintaining or improving reproductive function.

[0096] An embodiment of the present invention provides a use of a cycloastragenol, resveratrol, ginsenoside, tetrahydrocurcumin and cellulose composition in preparing an active ingredient for promoting glandular cell activity.

[0097] An embodiment of the present invention provides a use of a composition of cycloastragenol, resveratrol, ginsenoside, tetrahydrocurcumin and cellulose in preparing an active ingredient for promoting elastin synthesis.

[0098] An embodiment of the present invention provides a use of a composition of cycloastragenol, resveratrol, ginsenoside, tetrahydrocurcumin and cellulose in the preparation of an active ingredient for promoting glandular cell activity.

[0099] An embodiment of the present invention provides a use of a composition of cycloastragenol, resveratrol, ginsenoside, tetrahydrocurcumin and cellulose in preparing an active ingredient for protecting the postpartum reproductive system.

[0100] An embodiment of the present invention provides a use of a composition of cycloastragenol, resveratrol, ginsenoside, tetrahydrocurcumin and cellulose in the preparation of an active ingredient for enhancing the activity of smooth muscle and glandular cells.

[0101] The present invention provides an embodiment of a composition of cycloastragenol, resveratrol, ginsenoside, tetrahydrocurcumin and cellulose for use in preparing an active ingredient for enhancing telomerase activity and improving smooth muscle and glandular cell activity.

[0102] An embodiment of the present invention provides an application of cycloastragenol in the preparation of an active ingredient for enhancing telomerase activity and improving smooth muscle and gland cell activity.

[0103] An embodiment of the present invention provides a use of resveratrol in the preparation of an active ingredient for enhancing telomerase activity and improving smooth muscle and gland cell activity.

[0104] An embodiment of the present invention provides a use of ginsenoside in the preparation of an active ingredient for enhancing telomerase activity and improving smooth muscle and gland cell activity.

[0105] The embodiment of the present invention provides a use of tetrahydrocurcumin in the preparation of an active ingredient for enhancing telomerase activity and improving smooth muscle and gland cell activity.

[0106] An embodiment of the present invention provides an application of cellulose in the preparation of an active ingredient for enhancing telomerase activity and improving smooth muscle and gland cell activity.

[0107] 2. Relevant evidence of the technical effects obtained by the embodiments of the present invention.

[0108] Sample preparation: conventional technology was used to prepare solutions of cycloastragenol, resveratrol, ginsenoside, tetrahydrocurcumin, cellulose and the combination, all with a mass concentration of 5%, wherein the combination solution contained five monomers with a mass concentration of 1% each.

[0109] Statistical analysis was performed using GraphPad Prism version 8.0 software. All data were tested for normality and homogeneity of variance, and appropriate data transformation, independent-samples test, or one-way ANOVA were performed based on the results. In the statistical analysis, ### represents p < 0.001, ## represents p < 0.01, and # represents p < 0.05 compared with the normal group, which was the standard for statistical significance. Compared with the postpartum group (model group), *** represents p < 0.001, ** represents p < 0.01, and * represents p < 0.05, which was the standard for statistical significance.

[0110] Experimental Example 1: Studying the activity of samples using animal models

[0111] 1) At the animal level, the effects of cycloastragenol, resveratrol, ginsenosides, tetrahydrocurcumin and cellulose on promoting the activity of uterine and ovarian smooth muscle and reducing the damage of uterine and ovarian smooth muscle cells in postpartum mice were studied.

[0112] 70 postpartum SPF-grade ICR aged mice weighing 29-30 g were collected on the first day after delivery. They were housed in an independent ventilation system for experimental animals, with a room temperature of (23±2)°C, a humidity of 50%±5%, 12 hours of light and 12 hours of darkness per day, and free access to food and water. Animal experiments followed the regulations of the Animal Ethics Committee. 70 postpartum mice were randomly divided into a postpartum group (model group), a composition administration group, a cycloastragenol administration group, a resveratrol administration group, a ginsenoside administration group, a tetrahydrocurcumin administration group, and a cellulose administration group, with 10 mice in each group. The administration group was administered 0.1 ml vaginally using a gavage device once a day for a total of 2 weeks.

[0113] The body weights of the mice were recorded before and after administration. Figure 2 This figure compares the weight of mice in the postpartum and drug-treated groups before and after treatment. Statistical results show that after two weeks of the experiment, both the postpartum and drug-treated groups experienced an increase in weight, but there was no statistically significant difference between the two groups (p>0.05). This result indicates that there was no difference in weight between the randomly assigned groups of mice, and this had no adverse effect on the experimental results.

[0114] Mice were anesthetized by intraperitoneal injection of 10% chloral hydrate, and reproductive system tissues (vagina, uterus, ovary) were removed and the tissue morphology, color, and weight were recorded. Figure 3 These are anatomical diagrams and color and morphological comparison diagrams of the reproductive systems of normal mice, postpartum mice, and mice in the drug-treated group. The pictures show that the morphology and function of the reproductive system (vagina, uterus, and ovaries) of the mouse composition-treated group are significantly better than those of the postpartum group (model group). Figure 4Statistics were conducted on the weight of the reproductive system of mice. The results showed that the weight of the reproductive system of the group administered with the combination was significantly greater than that of the postpartum group (p<0.001). Under the same conditions, the weight increased by 46.7%. The weight of the reproductive system of the group administered with cycloastragenol was significantly greater than that of the postpartum group (p<0.05). Under the same conditions, the weight increased by 10%. The groups administered with the other four monomers showed an increasing trend in the total weight of the vagina, uterus and ovaries, but there was no statistically significant difference (p>0.05), indicating that the effects of the five monomers were weak and the effect of the combination was significantly enhanced. The experimental results show that the effects of the combination administration group were significantly different from those of the monomer administration group. The combination administration significantly improved the morphology and weight of the reproductive system of mice. This indicates that local application can increase the size of smooth muscle cells in the reproductive tract and increase the number of live cells in female animals after childbirth. Its mechanism is related to the resistance to smooth muscle cell traction damage and death caused by childbirth and the promotion of their growth.

[0115] 2) Effects of samples on smooth muscle contractile function

[0116] The biological signal acquisition and processing system was used to measure and calculate the in vitro uterine contraction tension within 5 minutes. Figure 5 This is a comparison of uterine contraction tension in postpartum mice. Statistical results show that the maximum and average uterine contraction tension in the group receiving the combination was significantly greater than in the group not receiving the combination (p<0.05). This experimental result demonstrates that the combination improved the contractile function of the reproductive system in mice. It also enhanced the function of vaginal smooth muscle, alleviated vaginal and uterine relaxation, and enhanced vaginal and uterine reproductive function.

[0117] 3) Pathological experiments on smooth muscle cells

[0118] The smooth muscle cells of the vaginal wall were counted by conventional pathological techniques and immunohistochemistry. Figure 6 The results of the statistical analysis of the percentage of damaged, atrophic, and apoptotic smooth muscle cells in mice showed that the percentage of damaged smooth muscle cells in the combination-treated group was significantly lower than that in the postpartum group (p<0.001). Under the same conditions, the percentage was reduced by 60.6%. The groups treated with the five monomers separately showed an improvement trend, but the effect was weaker than that in the combination-treated group. These experimental results indicate that vaginal smooth muscle cells in postpartum mice are severely damaged, with decreased vitality and number. The combination-treated group significantly improved vaginal smooth muscle cell vitality in mice, helping to resist damage.

[0119] 4) Effects of samples on serum muscle damage marker proteins

[0120] ELISA kits were used to detect serum markers such as smooth muscle troponin (sm-troponin) to measure smooth muscle damage, and endothelin (ET-1) to measure smooth muscle survival. Figure 7The sm-troponin content was statistically shown in the group administered with the combination, which was significantly lower than that in the postpartum group (p<0.001). The groups administered with the five monomers separately showed a decreasing trend, but the effect was weaker than that in the group administered with the combination. Figure 8 GraphPad Prism 10.0 software statistically analyzed endothelin (ET-1) levels in the combination-treated group compared to the postpartum group (p<0.001). Under the same conditions, sm-troponin levels increased by 28.2%. Groups treated with the five monomers showed an upward trend, but the effect was weaker than that of the combination-treated group, demonstrating that the activity of the combination sample is fundamentally different from that of the monomers. These results suggest that postpartum mice have damaged genital smooth muscle and that the combination-treated group promoted the growth and survival of genital smooth muscle cells, leading to weight gain.

[0121] 5) Effects of samples on vaginal immune function in mice

[0122] After two weeks of the experiment, all mice were fasted and deprived of water overnight. The next day, the vagina of each mouse was washed three times with 100 μL of normal saline, and the vaginal lavage fluid was collected and then stored at -80°C for subsequent analysis. Referring to the kit instructions, the double antibody sandwich method combined with the enzyme reader was used to detect the level of immunoglobulin A. The results are as follows Figure 9 As shown, compared with the postpartum group, after drug intervention in each group, especially the combination administration group, the immunoglobulin A level in the vaginal lavage fluid of mice was significantly increased (p<0.001). Under the same conditions, the immunoglobulin A level increased by 2 times, which shows that the combination intervention can regulate the immune response, effectively improve the immune function, reduce tissue damage, promote the proliferation and repair of vaginal smooth muscle cells and connective tissue cells, thereby reducing the degree of vaginal relaxation.

[0123] 6) Effects of samples on telomerase activity in mouse uterus and vagina

[0124] Real-time quantitative PCR (qPCR) was used to detect changes in telomerase activity in the mouse uterus and vagina. Figure 10 and Figure 11The figures are a comparison of the effects of the relative telomerase activity in the vagina and uterus of each group of mice. Statistical results show that the relative telomerase activity in the uterus and vagina of mice in the combination-administered group was significantly higher than that in the postpartum group (p<0.001). Under the same conditions, the telomerase activity in the uterus and vagina increased by 2.33 times and 2.67 times, respectively. The relative telomerase activity in the uterus and vagina of mice in the tetrahydrocurcumin-administered group was significantly higher than that in the postpartum group (p<0.001). Under the same conditions, the telomerase activity in the uterus and vagina increased by 1.33 times and 1.4 times, respectively. The other four monomer-administered groups showed a trend of improvement, but the effect was weaker than that in the combination-administered group and the tetrahydrocurcumin-administered group. These experimental results indicate that both the combination-administered group and the tetrahydrocurcumin-administered group have the effect of significantly increasing the relative telomerase activity in the vagina and uterus of mice, promoting the repair and regeneration of uterine tissue, protecting the elasticity and functional maintenance of vaginal tissue, and thus enhancing the reproductive function of the vagina and uterus.

[0125] 7) Effects of samples on HE staining of mouse ovaries and vagina

[0126] The ovaries and vaginas of mice were fixed with tissue fixative and stained with HE using the longitudinal section method. Figure 12 Comparative images of the ovaries and vaginas of normal mice, postpartum mice, and mice in the drug-treated group were obtained by HE staining. The images show that while the normal group had abundant and regular follicles, the postpartum group had a significant decrease in follicles, irregular morphology, and some follicles exhibited degenerative changes. The drug-treated groups had a partial recovery of follicles, with the changes being particularly pronounced in the group receiving the drug combination. Furthermore, the vaginal wall thickness in the mice receiving the drug combination was significantly higher than in the postpartum group (model group), and vaginal laxity was significantly improved. Figure 13 This is a statistical comparison chart of the number of follicles in each group of mice. The statistical results show that the increase in the number of follicles in the group receiving the combination was significantly greater than that in the group not receiving the combination after delivery, with statistical significance (p<0.01). This experimental result shows that the combination-treated group promoted the recovery of ovarian function in mice, improved the growth and development of ovarian follicles, and promoted the recovery of vaginal tissue elasticity and enhanced vaginal contraction, thereby restoring and improving the reproductive system function of the mice.

[0127] Experimental Example 2: Study on the promotion of postpartum mouse uterine and ovarian gland cell survival by the sample at the animal level

[0128] As in Experimental Example 1, after administration, the mice were fasted for 14 hours, anesthetized with 10% chloral hydrate, and blood was collected from the abdominal aorta. The serum was centrifuged at 3000 rpm for 10 minutes. The serum sex hormone levels of the mice before and after administration were detected according to the instructions of the estrogen (E) ELISA kit, and the sex hormone level data were compared and analyzed. Figure 14 and Figure 15The figures are a comparison of estradiol and testosterone levels in mice. Statistical results show that the testosterone and estradiol levels in the group administered with the combination were significantly higher than those in the normal group (p<0.001). Under the same conditions, the testosterone and estradiol levels increased by 1.05 times and 2 times, respectively. There was a trend of improvement in the groups administered with the five monomers separately, but the effect was weaker than that in the group administered with the combination. The experimental results show that the activity of the combination is significantly improved and is significantly better than that of the monomer compound. It can better help the proliferation and repair of uterine smooth muscle cells, prevent problems such as postpartum vaginal relaxation, and in addition, it can restore or improve endocrine balance, regulate the metabolism of postpartum mice, promote protein synthesis, and contribute to the recovery of the body and the repair of tissues.

[0129] Experimental Example 3: Studying the effects of samples on the number of viable cells and elastin synthesis in mouse vaginal smooth muscle at the cellular level

[0130] 1) Mouse vaginal smooth muscle cells were isolated from the vaginal wall muscularis using conventional primary culture techniques. Incubation was performed for 4 hours in a medium containing 5% CO2 and a final endotoxin concentration of 70 μL / mL to induce vaginal smooth muscle cell injury. The cells were divided into a normal group, a model group, a combination-treated group, a cycloastragenol-treated group, a resveratrol-treated group, a ginsenoside-treated group, a tetrahydrocurcumin-treated group, and a cellulose-treated group. Cell viability and growth were assessed using the CCK-8 assay. Absorbance (A) at a wavelength of λ460 was measured using a microplate reader. Cell viability was calculated as follows: Cell viability (%) = [A(treated well X) - A(blank well B)] / [A(normal group) - A(blank well B)] × 100%. Figure 16 This is a statistical chart of mouse vaginal smooth muscle cell activity. The statistical analysis results show that the activity of smooth muscle cells in the model group was significantly lower than that in the normal group (p<0.001). Under the same conditions, the activity of smooth muscle cells decreased by 54.5%, indicating that the endotoxin-induced vaginal smooth muscle cell injury model was successful. The number and activity of living cells in the combination-administered group were significantly higher than those in the model group (p<0.001). Under the same conditions, the activity of smooth muscle cells increased by 80%. There was a trend of improvement in the groups where the five monomers were administered separately, but the effect was weaker than that in the combination-administered group, proving that the activity of the combination sample was essentially different from that of the monomer, indicating that the combination can effectively protect cells from damage and promote the recovery of cell activity. The above phenomenon is related to the administration of the combination to counteract the reduction and atrophy of vaginal smooth muscle cells in aged mice after childbirth, proving the effect of the combination sample on the repair of vaginal smooth muscle cell damage in mice.

[0131] 2) To investigate the effects of the samples on elastin synthesis in smooth muscle cells, primary vaginal smooth muscle cells were cultured in 12-well plates using the same culture methods and cell dosing groups as described above. After dosing, the smooth muscle cells were incubated in an incubator for 72 hours. The supernatant was gently aspirated and the cells were labeled with a primary elastin antibody, followed by incubation with a fluorescent secondary antibody, as per standard procedures. Fluorescence was measured using a Molecular Devices Flexstation 3 screening workstation to measure the brightness of elastin precursors within the smooth muscle cells. The elastin content synthesized in and outside the smooth muscle cells was calculated by comparing the fluorescence brightness of the treated wells to the brightness of the control wells. The treated groups were compared with the model control group (no drug, only vehicle). The calculation formula is: Relative content of elastin and its precursors within and outside the cells (%) = [Brightness (treated well X) - Brightness (blank well B)] / [Brightness (normal group) - Brightness (blank well B)] × 100%. Figure 17 This is a statistical chart of the relative brightness of elastin and its precursors synthesized by primary mouse vaginal smooth muscle cells. Statistical analysis revealed a statistically significant increase in fluorescence brightness in the group receiving the combination (p<0.001). Under the same conditions, the fluorescence brightness increased 1.19-fold. The relative brightness of the groups receiving the five monomers individually also increased, but the effect was weaker than that of the group receiving the combination. This indicates that the ability of the combination to promote elastin synthesis in smooth muscle cells is greater than the activity of the monomers, resulting in a significant improvement. This suggests that elastin synthesis by vaginal smooth muscle cells and fibroblasts in postpartum individuals is significantly associated with vaginal laxity, suggesting potential application.

[0132] Experimental Example 4: Studying the Effects of Composition Samples on Uterine Gland Cells at the Cell Level

[0133] Endometrial glandular cells were prepared using a conventional primary culture method. Primary endometrial glandular cells were seeded in DMEM-F12 medium (with the double antibody and the combination) supplemented with 10% fetal bovine serum and placed in a humidified 37°C incubator with 5% CO2. The medium was changed after 24 hours. The cells were divided into a normal group, a combination group, a cycloastragenol group, a resveratrol group, a ginsenoside group, a tetrahydrocurcumin group, and a cellulose group. Cell viability was assessed using the CCK-8 assay. Absorbance at a wavelength of λ460 was measured using a microplate reader. Figure 18 This is a statistical chart of mouse endometrial glandular cell viability. The results show that the number and viability of live cells in the combination-treated group were significantly higher than in the normal group (p<0.001). Under the same conditions, endometrial glandular cell viability increased by 32%. While the five monomers administered separately showed an upward trend, the effect was weaker than that of the combination-treated group. This suggests that the combination of the five monomers significantly promotes the survival and growth of mouse glandular cells, significantly improving their activity compared to the activity of the individual monomers.

[0134] The above experiments have shown that the present invention provides a new formula component for preventing and treating injuries to the birth canal and reproductive tract, and maintaining the health of the female reproductive system. It can promote the survival of smooth muscle cells and glandular cells in the postpartum reproductive system, enhance the synthesis of elastin in smooth muscle cells, and can also combat postpartum vaginal smooth muscle damage and promote functional repair. Elastin synthesized by vaginal smooth muscle cells is an important component of vaginal elasticity. Elastin is the main component of elastic fibers and has an important impact on vaginal relaxation. Elastin is also beneficial for resisting relaxation of the reproductive system. Experiments have shown that the new use of cycloastragenol, resveratrol, ginsenosides, tetrahydrocurcumin and cellulose has a good effect on improving the vitality of vaginal smooth muscle and glandular cells in the reproductive system, and can enhance their survival and functional repair and maintenance.

[0135] The above description is only a specific embodiment of the present invention, but the scope of protection of the present invention is not limited thereto. Any modifications, equivalent substitutions and improvements made by any technician familiar with this technical field within the technical scope disclosed by the present invention and within the spirit and principles of the present invention should be covered by the scope of protection of the present invention.

Claims

1. A composition having a cell-protective effect, characterized in that: According to the mass percentage, it includes 0.1% to 5% of cycloastragenol, 0.5% to 10% of resveratrol, 0.1% to 5% of ginsenoside, 0.1% to 2% of tetrahydrocurcumin, and 1% to 10% of cellulose.

2. A composition having a cell-protective effect, characterized in that: The composition consists of 0.1% to 5% of cycloastragenol, 0.5% to 10% of resveratrol, 0.1% to 5% of ginsenoside, 0.1% to 2% of tetrahydrocurcumin, 1% to 10% of cellulose, 1.7% to 2.2% of a moisturizing composition and the balance of purified deionized water in parts by mass.

3. The composition having a cell-protective effect according to claim 2, wherein The moisturizing composition consists of hyaluronic acid and collagen.

4. A composition having a cell-protective effect, characterized in that: The composition consists of 0.1% to 5% of cycloastragenol, 0.5% to 10% of resveratrol, 0.1% to 5% of ginsenoside, 0.1% to 2% of tetrahydrocurcumin, 1% to 10% of cellulose, 12% to 22% of a moisturizing composition and the balance of purified deionized water in parts by mass.

5. The composition having a cell-protective effect according to claim 4, wherein The mass fraction of the moisturizing composition is 12% to 22%, and the composition components can be composed of any two or more of sucrose, sorbitol, glycerol, propylene glycol, chondroitin sulfate, hyaluronic acid, sulfated mucopolysaccharide, carolinic acid, and atelocollagen.

6. A method for preparing the composition having a cell-protective effect as claimed in claim 1, characterized in that: include: Cycloastragenol, resveratrol, ginsenoside, tetrahydrocurcumin and cellulose are mixed with distilled water and stirred uniformly to obtain a composition of the cycloastragenol, resveratrol, ginsenoside, tetrahydrocurcumin and cellulose.

7. A method for preparing the composition having a cell-protective effect according to any one of claims 2 to 5, characterized in that: The preparation method specifically comprises the following steps: Step 1, weighing cycloastragenol, resveratrol, ginsenoside, tetrahydrocurcumin, cellulose, and a moisturizing composition or a moisturizing composition according to proportion; Step 2: dissolving cycloastragenol, resveratrol, ginsenosides, tetrahydrocurcumin and cellulose in a water replenishing composition or a moisturizing composition solution, and stirring to obtain a homogeneous solution; Step 3: Add purified ionized water to the homogeneous solution to a full amount and adjust the volume to obtain the cycloastragenol, resveratrol, ginsenoside, tetrahydrocurcumin and cellulose composition.

8. Use of the composition with cell protection effect according to any one of claims 1 to 5 in the preparation of products related to repairing reproductive tract cell damage and promoting vaginal smooth muscle cell production, which acts by promoting smooth muscle to synthesize elastin.

9. Use of the composition with cytoprotective effect according to any one of claims 1 to 5 in the preparation of products related to promoting the activity of uterine and reproductive tract gland cells, through direct cytoprotective effect.

10. The use of the composition with cytoprotective effects as described in any one of claims 1 to 5 in the preparation of products related to promoting the recovery of glandular secretory function, wherein the composition acts by activating the telomerase activity of the reproductive tract glands and thereby promoting the lubricating fluid production function; the use of the composition with cytoprotective effects in the preparation of products related to accelerating postpartum reproductive tract recovery exerts its effects by enhancing immunity and restoring or improving the endocrine balance of the reproductive system.

Images